		Docket Number (Optional)	Application Number			
ø :	· -	MST-2393 US	10/723,795			
	REPORTION DISCLOSURE CITATION	Applicant(s)				
	(Use everal sheets if necessary)	Supuran et al. Filing Date Group Art Unit				
SZ FEB	0 9 2004 🛣	November 26, 2003				
*EXAMINER	OTHER DOCUMENTS (Including Author, Tith	e, Date, Pertinent Pages, Etc.)				
B	Pressure-Lowering Agents with Long-Lasting Effect	er-Soluble 4-Sulfamoylphenylthioure	as as Topical Intraocular			
BF	·					
BF	Chegwidden et al., "The Roles of Carbonic Anhydrase Isozymes in Cancer," Gene Families: Studies of DNA, RNA, Enzymes and Proteins, Proceedings of the International Isozymes, 10th, Beijing, China, Oct. 5-10, 1999, Meeting Date 1999, 157-169 (Xue, G. ed.; World Scientific Pub. Co.; 2001)					
BF	Clare and Supuran, "Carbonic anhydrase iinhibito benzenedisulfonamides," <u>Eur. J. Med. Chem., 34</u> : 4	Clare and Supuran, "Carbonic anhydrase iinhibitors. Part 61. Quantum chemical QSAR of a group of benzenedisulfonamides," <u>Eur. J. Med. Chem., 34</u> : 463-474 (1999)				
. BF	551(Pt 1): 79-92 (2003 Aug 15)	Cuthbert et al., "Bicarbonate-dependent chloride secretion in Calu-3 epithelia in response to 7,8-benzoquinoline," <u>J Physiol., 551</u> (Pt 1): 79-92 (2003 Aug 15)				
BF	Franchi et al., "Carbonic Anhydrase Inhibitors. Inl Cancer-associated Isozyme IX with Lipophilic Sulfo 333-338 (Aug. 2003)	Franchi et al., "Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Cancer-associated Isozyme IX with Lipophilic Sulfonamides," <u>Journal of Enzyme Inhibition and Medicinal Chemistry, 18</u> (4): 333-338 (Aug. 2003)				
BF	Ilies et al., "Carbonic Anhydrase Inhibitors. Inhibitors. Halogenophenylaminobenzolamide Derivatives," <u>J.</u>	Illies et al., "Carbonic Anhydrase Inhibitors. Inhibition of Tumor-Associated Isozyme IX by Halogenosulfanilamide and Halogenophenylaminobenzolamide Derivatives," J. Med. Chem., 46: 2187-2196 (2003)				
BF	Pastorek et al., "Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment," Oncogene, 9: 2877-2888 (1994)					
BF	Scozzafava and Supuran, "Carbonic Anhydrase Inhibitors: Synthesis of N-Morpholylthlocarbonylsulfenylamino Aromatic/Heterocyclic Sulfonamides and their Interaction with Isozymes I, II and IV," Bioorganic & Medicinal Chemistry Letters, 10: 1117-1120 (2000)					
BF	Pressure_Lowering Aromatic/Heterocyclic Sullona	Scozzafava et al., "Carbonic Anhydrase Inhibitors. Synthesis of Water-Soluble, Topically Effective, Intraocular Pressure-Lowering Aromatic/Heterocyclic Sulfonamides Containing Cationic or Anionic Moleties: Is the Tail More Important than the Ring?" J. Med. Chem., 42: 2641-2650 (1999)				
BF	Scozzafava et al., "Carbonic Anhydrase Inhibitors: Synthesis of Membrane-Impermeant Low Molecular Weight Sulfonamides Possessing in Vivo Selectivity for the Membrane-Bound versus Cytosolic Isozymes," J. Med. Chem., 43: 292-300 (Jan. 27, 2000)					
BF	II," Am. J. Physiol. Cell Physiol., 283(5): C1522-C	Sterling et al., "The functional and physical relationship between the DRA bicarbonate transporter and carbonic anhydrase II," Am. J. Physiol. Cell Physiol., 283(5): C1522-C1529 (Nov. 2002)				
BF	Supuran and Clare, "Carbonic anhydrase inhibitors. Part 24. A quantitative structure-activity relationship study of positively charged sulfonamide inhibitors," <u>Eur. J. Med. Chem., 30</u> : 687-696 (1995)					
EXAMINER	/Brandon Fetterolf/	DATE CONSIDERED 01/23/20	007			
		LA MADERO COLO COS DE UNIO	through situation if not in conformance and			
*EXAMINER: In not considered.	nitial if citation considered, whether or not citation is in conformatic in conformatic in copy of this form with next communication to applicant.	ance with MPEP Section 609; Draw line (nrough citation ii not in conformance and			

"OIP	Ē.	Docket Number (Optional) MST-2393 US	Application Number 10/723,795				
INFOR	MARKON DISCLOSURE CITATION	Applicant(s)					
FEB 0 9	everal sheets if necessary)	Supuran et al.	Group Art Unit				
FEB 0 9		November 26, 2003					
*EX MONED	OTHER DOCUMENTS (Including Author, Ti	ile, Date, Pertinent Pages, Etc.)					
BF	Supuran and Clare, "Carbonic anhydrase inhibitors - Part 57: Quantum chemical QSAR of a group of 1,3,4-thiadiazole- and 1,3,4-thiadiazoline disulfonamides with carbonic anhydrase inhibitory properties," Eur. J. Med. Chem., 34: 41-50 (1999)						
BF	Supuran and Scozzafava, "Carbonic Anhydrase Inhibitors: Aromatic Sulfonamides and Disulfonamides Act as Efficient Tumor Growth Inhibitors," J. Enzyme Inhib., 15(6): 597-610 (2000)						
BF	Supuran and Scozzafava, "Carbonic anhydrase inhibitors - Part 94. 1,3,4-Thiadiazole-2-sulfonamide derivatives as antitumor agents?," Eur. J. Med. Chem., 35(9):867-874 (Sept. 2000)						
BF	Supuran et al., "Carbonic anhydrase inhibitors – Part 53. Synthesis of substituted-pyridinium derivatives of aromatic sulfonamides: The first non-polymeric membrane-impermeable inhibitors with selectivity for isozyme IV," Eur. J. Med.Chem., 33 : 577-594 (1998)						
BF	Supuran et al., "Carbonic anhydrase inhibitors - Part 29: Interaction of isozymes I, II and IV with benzolamide-like derivatives," <u>Eur. J. Med. Chem., 33</u> : 739-751 (1998)						
BF	Supuran et al., "Carbonic Anbydrase Inhibitors: Synthesis of Sulfonamides Incorporating 2,4,6-Trisubstituted-Pyridinium-Ethylcarboxamido Moleties Possessing Membrane-Impermeability and In Vivo Selectivity for the Membrane-Bound (CA IV) Versus the Cytosolic (CA I and CA II) Isozymes," J. Enzyme Inhibition, 15(4): 381-401 (2000)						
BF	Supuran et al., "Carbonic Anhydrase Inhibitors: Sulfonamides as Antitumor Agents?," <u>Bioorganic & Medicinal Chemistry, 9(</u> 3): 703-714 (March 2001)						
BF	Supuran et al., "Carbonic Anhydrase Inhibitors," Medicinal Research Reviews, 23(2): 146-189 (March 2003)						
BF	Teicher et al., "A Carbonic Anhydrase Inhibitor as a Potential Modulator of Cancer Therapies," Anticancer Research, 13: 1549-1556 (1993)						
BF	Vullo et al., "Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Cancer-associated Isozyme IX with Anions," <u>Journal of Enzyme Inhibition and Medicinal Chemistry</u> , 18(5): 403-406 (Oct. 2003)						
BF	Vullo et al., "Carbonic Anhydrase Inhibitors: Inhibition of the Tumor-Associated Isozyme IX with Aromatic and Heterocyclic Sulfonamides," <u>Bioorganic Medicinal Chemistry Letters, 13(6)</u> : 1005-1009 (March 24, 2003)						
BF	Wingo et al., "The Catalytic Properties of Human Carbonic Anhydrase IX," Biochemical and Biophysical Research Communications, 288: 666-669 (2001)						
EXAMINER	/Brandon Fetterolf/	DATE CONSIDERED 01/23/	2007				
*EXAMINER: Ini	tial if citation considered, whether or not citation is in confor	mance with MPEP Section 609; Draw lie	ne through citation if not in conformance and				

not considered. Include copy of this form with next communication to applicant.

MST-2393 US MST-2393 US MST-2393 US 10/723,795 Applicatis) Supuran et al. FIB 0 9 2004 OTHER DOCUMENTS (Including Author, Title, Date, Perinent Pages, Etc.) Tumor-Associated Isozyme Ix with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors, " J. Med. Chem., 48(11): 2197-2204 (May 22, 2003) Wistrand and Lindqvist, "Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase - From Biochemistry and Genetics to Physiology and Clinical Medicine, Botrè et al., Eds., VCH, Weinheim, pp. 352-378 (1991) Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
FEB 0 9 2004 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) November 26, 2003 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Purmor-Associated Isozyme Ix with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors, "J. Med. Chem., 46(11): 2197-2204 (May 22, 2003) Wistrand and Lindqvist, "Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase — From Biochemistry and Genetics to Physiology and Clinical Medicine, Botre et al., Eds., VCH, Weinhelm, pp. 352-378 (1991) Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
FEB 0 9 2004 OTHER DOCUMENTS (Including Author, Title, Date, Perlinent Pages, Etc.) Winum et al., "Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme Ix with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors," J. Med. Chem., 46(11): 2197-2204 (May 22, 2003) Wistrand and Lindqvist, "Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase - From Blochemistry and Genetics to Physiology and Clinical Medicine, Botrè et al., Eds., VCH, Weinheim, pp. 352-378 (1991) Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
OTHER DOCUMENTS (Including Author, Tule, Date, Pertinent Pages, Etc.) Winum et al., "Carbonic Anhydrase Inhibitors. Inhibition of Cytosolic Isozymes I and II and Transmembrane, Tumor-Associated Isozyme Ix with Sulfamates Including EMATE Also Acting as Steroid Sulfatase Inhibitors," J. Med. Chem., 46(11): 2197-2204 (May 22, 2003) Wistrand and Lindqvist, "Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase - From Biochemistry and Genetics to Physiology and Clinical Medicine, Botrè et al., Eds., VCH, Weinbeim, pp. 352-378 (1991) Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
Wistrand and Lindqvist, "Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase – From Biochemistry and Genetics to Physiology and Clinical Medicine, Botrè et al., Eds., VCH, Weinheim, pp. 352-378 (1991) Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
Wistrand and Lindqvist, "Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase - From Biochemistry and Genetics to Physiology and Clinical Medicine, Botre et al., Eds., VCH, Weinheim, pp. 352-378 (1991) Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
Wistrand and Lindqvist, "Design of Carbonic Anhydrase Inhibitors and the Relationship Between the Pharmacodynamics and Pharmacokinetics of Acetazolamide," In Carbonic Anhydrase – From Blochemistry and Genetics to Physiology and Clinical Medicine. Medicine. Botrè et al., Eds., VCH, Weinheim, pp. 352-378 (1991) Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
Wu et al., Cytoplasmic pH Responses to Carbonic Anhydrase Inhibitors in Cultured Rabbit Nonpigmented Ciliary Epithelium," J. Membrane Biol., 162: 31-38 (1998)
·
EXAMINER /Prandon Retterolf/
/Brandon Fetterolf/ 01/23/2007
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and

P09B/REV04

not considered. Include copy of this form with next communication to applicant.

Mar Ordanistion Production Commission				MST-2393 US 10/723,795 Applicant(s) Claudiu Supuran et al.						
				November 26, 2003 1636						
		MR 13 MON SA	U.	S. PATENT	DOCUMENTS			<u> </u>		
EXAMINER INITIAL	REF	DOCUMENT NEWBER	DATE	NAME		CLASS	CLASS SUBCLASS		FILING DATE IF APPROPRIATE	
BF		6,034,099	03/07/00	Pamukcu and Piazza		514/310	514/313	11/24/98		
			 	-			 			
								<u> </u>		
							-			
			U.S. PATEN	T APPLIC	ATION PUBLICATIONS			· ·		
EXAMINER REF		DOCUMENT NUMBER DATE		:	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE		
					_					
				1.						
			·	FICN PATI	ENT DOCUMENTS			<u> </u>		
FOREIGN PATENT DOCUMENTS Translation										
	REP	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	YES	NO	
		·								
	 									
	<u></u>	<u> </u>	OTHER	DOCUME	NTS (Including A	uthor, Title, Date,	Pertinent Pages, I	E(c.)		
										
				,						
EXAMINER /Brandon Fetterolf/			DATE CONSIDERED 01/23/2007							
EXAMINI not consid	ER: Ini lered. I	tial if citation considered, wheth nclude copy of this form with no	er or not citation is ext communication (in conform to applicant	ance with MPEP Section 6	609; Draw line thr	ough citation if a	ot in conform	ance and	

Docket Number (Optional)

Application Number